Liminal BioSciences Inc.and Structured Alpha LP a fund managed by Thomvest Asset Management Ltd., today announced that they have entered into a definitive arrangement

Bridge Biotherapeutics, a South Korean clinical-stage biotech company developing novel drugs for fibrosis, cancer and inflammation, announced that it has joined PROLIFIC, the Prognostic Lung Fibrosis Consortium, an organization devoted to boosting scientific exploration

Redwood Scientific Technologies Inc., a pioneering pharmaceutical company based in New York, is proud to announce the filing of a new patent for its cutting-edge Oral Thin Film (OTF) manufacturing system. The patent showcases Redwood's commitment to revolutionizing

Zhejiang Doer Biologics Co., Ltd. a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announced that it has entered into a license agreement with BioNTech SE.

Astellas Pharma Inc. and 4D Molecular Therapeutics, Inc. today announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100*

Today, the US Food and Drug Administration converted the approval process for Leqembi indicated for the treatment of adult patients with Alzheimer's disease, is on traditional approval after a confirmatory study verified clinical benefit.

NS Pharma, Inc. announced today the U.S. Food & Drug Administration has granted Rare Pediatric Disease Designation to NS-089/NCNP-02 (brogidirsen) an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.

South Rampart Pharma, Inc. a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that the China National Intellectual

Asieris Pharmaceuticals a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related

BioArctic AB's partner Eisai announced today that the U.S. Food and Drug Administration, FDA, has approved the supplemental Biologics License Application, sBLA, supporting the traditional